# A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

> **NCT03891173** · PHASE2 · TERMINATED · sponsor: **Helix BioPharma Corporation** · enrollment: 9 (actual)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

- **DRUG:** L-DOS47
- **DRUG:** Cisplatin
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT03891173
- **Lead sponsor:** Helix BioPharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-19
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study was halted at this time due to other budgetary priorities. Completion of reporting has been delayed first due to covid restrictions and more recently due to war in Ukraine.
- **Last updated:** 2022-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891173, "A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT03891173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*